title: Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
abstract: This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed the medical records of 300 malignant glioma patients treated with temozolomide in two medical institutions in Korea between 2004 and 2010. Two hundred nine patients experienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the 618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2, while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia (13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the non-hematologic toxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were the three most common toxicities. There was no mortality due to temozolomide. Although temozolomide showed many types of toxicities, the majority of the toxicities were tolerable and of lower grade. Gastrointestinal troubles are the most common toxicities in Korean patients treated with temozolomide.
authors.affiliation: Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea.
authors.forename: So Hyun
authors.identifier: 0000-0001-9842-6584
authors.initials: SH
authors.lastname: Bae
authors.affiliation: Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea.
authors.forename: Min-Jung
authors.identifier: 0000-0003-1638-3491
authors.initials: MJ
authors.lastname: Park
authors.affiliation: Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea.
authors.forename: Min Mi
authors.identifier: 0000-0003-3467-8859
authors.initials: MM
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Tae Min
authors.identifier: 0000-0001-6145-4426
authors.initials: TM
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Se-Hoon
authors.identifier: 0000-0002-9219-3350
authors.initials: SH
authors.lastname: Lee
authors.affiliation: Department of Neurosurgery, Dong-Eui Medical Center, Busan, Korea.
authors.forename: Sung Yun
authors.identifier: 0000-0001-8239-1639
authors.initials: SY
authors.lastname: Cho
authors.affiliation: Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Young-Hoon
authors.identifier: 0000-0002-8852-6503
authors.initials: YH
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Yu Jung
authors.identifier: 0000-0002-5037-0523
authors.initials: YJ
authors.lastname: Kim
authors.affiliation: Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Chul-Kee
authors.identifier: 0000-0002-2350-9876
authors.initials: CK
authors.lastname: Park
authors.affiliation: Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea. ; Seoul National University College of Medicine, Seoul National University, Seoul, Korea.
authors.forename: Chae-Yong
authors.identifier: 0000-0001-9773-5553
authors.initials: CY
authors.lastname: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000855:Anorexia / Q000209:etiology; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D009367:Neoplasm Staging; D056910:Republic of Korea; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012737:Sex Factors; D000077204:Temozolomide; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
keywords: Chemoradiotherapy; Chemotherapy, Adjuvant; Glioma; Temozolomide; Toxicity